COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00073931
Recruitment Status : Completed
First Posted : December 11, 2003
Last Update Posted : February 5, 2015
National Cancer Institute (NCI)
Information provided by:
Fred Hutchinson Cancer Research Center

Brief Summary:

RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can locate cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells. Combining a radiolabeled monoclonal antibody with autologous stem cell transplantation may be an effective treatment for non-Hodgkin's lymphoma.

PURPOSE: Phase II trial to study the effectiveness of combining iodine I 131 tositumomab with autologous stem cell transplantation in treating older patients who have relapsed or refractory non-Hodgkin's lymphoma.

Condition or disease Intervention/treatment Phase
Lymphoma Biological: filgrastim Biological: sargramostim Procedure: autologous bone marrow transplantation Procedure: peripheral blood stem cell transplantation Radiation: tositumomab and iodine I 131 tositumomab Phase 2

Detailed Description:



  • Determine the progression-free survival of older patients with relapsed or refractory non-Hodgkin's lymphoma treated with iodine I 131 tositumomab followed by autologous stem cell transplantation.


  • Determine the overall survival of patients treated with this regimen.
  • Determine the toxicity and tolerability of this regimen in these patients.


  • Radioimmunotherapy: Patients receive a test dose of iodine I 131 tositumomab on day -24 to determine biodistribution. Patients then receive therapeutic iodine I 131 tositumomab IV over 1 hour on day -14 and are entered into radiation isolation until day -4.
  • Autologous stem cell transplantation: Patients undergo autologous bone marrow or peripheral blood stem cell transplantation on day 0. Patients undergoing bone marrow transplantation receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously beginning on day 0 and continuing until blood counts recover.

Patients are followed at 1, 3, 6, and 12 months and then annually thereafter.

PROJECTED ACCRUAL: A total of 24-30 patients will be accrued for this study within 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial Evaluating: Radioiodinated Anti-B1 (Anti-CD20) Antibody With Autologous Stem Cell Transplantation For Relapsed Or Refractory Non-Hodgkin's Lymphoma In Patients 60 Years Of Age And Older
Study Start Date : October 1999
Actual Primary Completion Date : May 2007
Actual Study Completion Date : July 2014

Intervention Details:
  • Biological: filgrastim
    5 µg/kg/day subcutaneously
    Other Name: G-CSF
  • Biological: sargramostim
    250µg/m2/d subcutaneously
    Other Name: GM-CSF
  • Procedure: autologous bone marrow transplantation
    autologous stem cells given via central catheter
  • Procedure: peripheral blood stem cell transplantation
    autologous stem cells given via central catheter
  • Radiation: tositumomab and iodine I 131 tositumomab
    given intravenously (test dose of 1.7-10 mg/kg tositumomab antibody radiolabeled with ~10 mCi I-131) or via central catheter (therapy dose of 1.7-10 mg/kg tositumomab radiolabeled with individually calculated therapy dose of I-131)

Primary Outcome Measures :
  1. Disease-free survival measured continuously [ Time Frame: from date of transplant through date of death ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed non-Hodgkin's lymphoma
  • CD20+ disease
  • Failed at least 1 prior standard systemic therapy
  • Persistent lymphoma by physical examination, radiographic studies, bone marrow evaluations, flow cytometry, or polymerase chain reaction
  • Tumor burden less than 500 cc by computed tomography or MRI

    • No splenomegaly
  • Autologous hematopoietic stem cells or bone marrow harvested and cryopreserved

    • No circulating lymphoma cells by morphology or flow cytometry at or near the time of peripheral blood stem cell (PBSC) collection if unpurged PBSCs are to be used
    • 10% or less marrow involvement by flow cytometry or morphology if purged bone marrow is to be used
  • No CNS lymphoma
  • No chronic lymphocytic leukemia or small lymphocytic lymphoma/well-differentiated lymphocytic lymphoma



  • 60 to 80

Performance status

  • SWOG 0-1

Life expectancy

  • More than 60 days


  • See Disease Characteristics


  • Bilirubin less than 1.5 mg/dL


  • Creatinine less than 2.0 mg/dL


  • No active coronary artery disease


  • FEV_1 at least 70% of expected
  • Vital capacity at least 70% of expected


  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • Able to perform self-care during radiation isolation
  • No major organ dysfunction
  • No major infection
  • No circulating anti-mouse antibody
  • No other serious medical condition considered to represent contraindications to bone marrow transplantation
  • No competing causes of death that would predict life span to be less than 10 additional years


Biologic therapy

  • No prior bone marrow or stem cell transplantation


  • Not specified

Endocrine therapy

  • Not specified


  • No prior radiotherapy greater than 20 Gy to any critical normal organ (e.g., lung, liver, spinal cord, or more than 25% of red marrow)


  • Not specified


  • More than 30 days since prior systemic antilymphoma therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00073931

Layout table for location information
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109-1024
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Ajay K. Gopal, MD Fred Hutchinson Cancer Research Center
Publications of Results:
Layout table for additonal information Identifier: NCT00073931    
Other Study ID Numbers: 1366.00
CDR0000341125 ( Registry Identifier: PDQ )
First Posted: December 11, 2003    Key Record Dates
Last Update Posted: February 5, 2015
Last Verified: February 2015
Keywords provided by Fred Hutchinson Cancer Research Center:
recurrent adult diffuse large cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent adult diffuse small cleaved cell lymphoma
recurrent adult Burkitt lymphoma
recurrent adult immunoblastic large cell lymphoma
recurrent adult lymphoblastic lymphoma
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent grade 3 follicular lymphoma
recurrent mantle cell lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Iodine-131 anti-B1 antibody
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents